EMA had nearly twice as many drug approvals as FDA in 2013
European drug agency EMA green-lighted almost twice as many new drug applications as its US counterpart FDA last year. It might be due to a “drag-out” effect, says top industry advisor Steffen Thirstrup.
by Morten Bang Jørgensen
Last week, numbers for new drug approvals by the US drug agency FDA were released, showing a dip in new approvals from 39 in 2012 to just 27 last year.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
New head of drug approvals appointed
For abonnenter
Thirstrup: EMA more welcoming towards the industry
For abonnenter
Top advisor warns against arrogance towards EU
For abonnenter
